# Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects

> **NCT06916273** · PHASE1 · COMPLETED · sponsor: **Anhui Palo Alto Pharmaceuticals, Inc.** · enrollment: 40 (actual)

## Conditions studied

- Bronchial Asthma

## Interventions

- **DRUG:** PA9159 Inhalation aerosol, 60 μg one day treatment
- **DRUG:** PA9159 Inhalation aerosol, 120 μg one day treatment
- **DRUG:** PA9159 Inhalation aerosol, 240 μg one day treatment
- **DRUG:** PA9159 Inhalation aerosol, 300 μg one day treatment
- **DRUG:** PA9159 Inhalation aerosol, 120 μg 7-day treatment
- **DRUG:** Placebo, the same Inhalation aerosol solution without PA9159 active ingredient

## Key facts

- **NCT ID:** NCT06916273
- **Lead sponsor:** Anhui Palo Alto Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2024-07-22
- **Primary completion:** 2024-09-12
- **Final completion:** 2024-09-21
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2025-12-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06916273

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06916273, "Safety, Tolerability, and Pharmacokinetics of PA9159 Inhalation Aerosol in Healthy Adult Subjects". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06916273. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*